Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $33.81 USD
Change Today +0.28 / 0.84%
Volume 1.2M
SRPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Christopher Nishan Garabedian

AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

48$5,003,026
As of Fiscal Year 2014

Background*

Mr. Christopher Nishan Garabedian, also known as Chris, had been the Chief Executive Officer and President of Sarepta Therapeutics, Inc. since January 1, 2011. Mr. Garabedian served as Vice President of Corporate Strategy at Celgene Corporation since July 2007. From November 2005 to June 2007, he served as an Independent Consultant to early-stage biopharmaceutical companies. From 1997 to November 2005, he served at Gilead Sciences, Inc., where he served in a number of ...

Read Full Background

Corporate Headquarters*

215 First Street
Cambridge, Massachusetts 02142

United States

Phone: 617-274-4000
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

BS
University of Maryland

Other Affiliations*

Annual Compensation*

Salary$603,200
Total Annual Compensation$603,200

Stock Options*

All Other Compensation$119,492
Exercisable Options572,778
Exercisable Options Value$1,521,874
Unexercisable Options423,055
Unexercisable Options Value$574,487
Total Value of Options$2,096,361
Total Number of Options1,160,021

Total Compensation*

Total Annual Cash Compensation$1,012,228
Total Short Term Compensation$603,200
Other Long Term Compensation$119,492
Total Calculated Compensation$5,003,026
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRPT:US $33.81 USD +0.28

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive (leave of absence) and Director
Silence Therapeutics plc
200.0K GBP
Mark W. Schwartz Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
$707.1K
Mark Joseph Murray Ph.D.Chief Executive Officer, President and Director
Arbutus Biopharma Corporation
$580.0K
Paul C. Grint M.D.Chief Executive Officer, President and Director
Regulus Therapeutics Inc.
--
Douglas M. Fambrough III, Ph.D.Co-Founder, Chief Executive Officer, President and Director
Dicerna Pharmaceuticals, Inc.
$430.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.